Published in

Springer, Investigational New Drugs, 4(33), p. 921-930, 2015

DOI: 10.1007/s10637-015-0255-1

Links

Tools

Export citation

Search in Google Scholar

Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors

Journal article published in 2015 by Khanh Do, Giovanna Speranza, Lun-Ching Chang, Eric C. Polley, Rachel Bishop, Weimin Zhu, Jane B. Trepel, Sunmin Lee, Min-Jung Lee, Robert J. Kinders, Larry Phillips, Jerry Collins, John Lyons, Woondong Jeong, Ramya Antony and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO